Elamin H Elbasha

List of Publications by Year
in descending order

46	2,568	257450	243625
papers	citations	24 h-index	44 g-index

47	47	47	2984
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Costâ€'Effectiveness Riskâ€'Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches. Pharmacoeconomics, 2022, 40, 497-507.	3.3	6
2	Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom. Vaccine, 2022, 40, 2173-2183.	3.8	4
3	Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine, 2021, 39, 438-446.	3.8	16
4	A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations. Infectious Disease Modelling, 2021, 6, 148-168.	1.9	98
5	Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. Human Vaccines and Immunotherapeutics, 2021, 17, 1943-1951.	3.3	24
6	Mathematical assessment of the impact of cohort vaccination on pneumococcal carriage and serotype replacement. Journal of Biological Dynamics, 2021, 15, S214-S247.	1.7	0
7	Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study. Vaccine, 2021, 39, 6315-6321.	3.8	3
8	Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infectious Diseases, 2021, 21, 11.	2.9	17
9	Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. Journal of Infection and Public Health, 2019, 12, 502-508.	4.1	1
10	Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach. BMC Infectious Diseases, 2018, 18, 119.	2.9	9
11	Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview. Pharmacoeconomics, 2017, 35, 673-683.	3.3	13
12	Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health, 2017, 20, 1110-1120.	0.3	14
13	Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers. Pharmacoeconomics, 2016, 34, 13-22.	3.3	18
14	Changing Cycle Lengths in State-Transition Models. Medical Decision Making, 2016, 36, 952-964.	2.4	38
15	The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases, 2016, 62, 298-304.	5.8	46
16	Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods. Medical Decision Making, 2016, 36, 115-131.	2.4	23
17	Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon-Î±2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore. Antiviral Therapy, 2015, 20, 209-216.	1.0	13
18	Public Health Impact and Cost-Effectiveness of Hepatitis A Vaccination in the United States: A Disease Transmission Dynamic Modeling Approach. Value in Health, 2015, 18, 358-367.	0.3	32

#	Article	IF	Citations
19	Characterizing Heterogeneity Bias in Cohort-Based Models. Pharmacoeconomics, 2015, 33, 857-865.	3.3	4
20	The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan. Value in Health Regional Issues, 2013, 2, 92-97.	1.2	6
21	Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 2013, 57, 2164-2170.	7.3	397
22	Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. Applied Health Economics and Health Policy, 2013, 11, 65-78.	2.1	34
23	Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. Value in Health, 2013, 16, 973-986.	0.3	63
24	Model for hepatitis C virus transmissions. Mathematical Biosciences and Engineering, 2013, 10, 1045-1065.	1.9	28
25	Qualitative analysis of an age- and sex-structured vaccination model for human papillomavirus. Discrete and Continuous Dynamical Systems - Series B, 2013, 18, 2151-2174.	0.9	7
26	Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Medicine, 2011, 9, 54.	5.5	37
27	The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. Journal of Medical Economics, 2010, 13, 110-118.	2.1	23
28	Impact of vaccinating boys and men against HPV in the United States. Vaccine, 2010, 28, 6858-6867.	3.8	192
29	Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infectious Diseases, 2009, 9, 119.	2.9	120
30	Age-Based Programs for Vaccination against HPV. Value in Health, 2009, 12, 697-707.	0.3	27
31	Global Stability of Equilibria in a Two-Sex HPV Vaccination Model. Bulletin of Mathematical Biology, 2008, 70, 894-909.	1.9	34
32	A Multi-Type HPV Transmission Model. Bulletin of Mathematical Biology, 2008, 70, 2126-2176.	1.9	54
33	Vaccination and the evolutionary ecology of human papillomavirus. Vaccine, 2008, 26, C25-C30.	3.8	20
34	Structural differences among costâ€“effectiveness models of human papillomavirus vaccines. Expert Review of Vaccines, 2008, 7, 895-913.	4.4	14
35	Assessment of the costâ€“effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 491-500.	1.4	26
36	Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 709-715.	2.5	83

#	Article	IF	Citations
37	Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine, 2007, 26, 128-139.	3.8	81
38	Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infectious Agents and Cancer, 2007, 2, 15.	2.6	57
39	Model for Assessing Human Papillomavirus Vaccination Strategies. Emerging Infectious Diseases, 2007, 13, 28-41.	4.3	419
40	Theoretical Assessment of Public Health Impact of Imperfect Prophylactic HIV-1 Vaccines with Therapeutic Benefits. Bulletin of Mathematical Biology, 2006, 68, 577-614.	1.9	93
41	Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and Disease. Epidemiologic Reviews, 2006, 28, 88-100.	3.5	146
42	Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. Health Economics (United Kingdom), 2005, 14, 457-470.	1.7	20
43	Vaccination against multiple HPV types. Mathematical Biosciences, 2005, 197, 88-117.	1.9	87
44	Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Economics (United Kingdom), 2004, 13, 21-35.	1.7	43
45	On Endogenous Growth: The Implications of Environmental Externalities. Journal of Environmental Economics and Management, 1996, 31, 240-268.	4.7	70
46	Authorsâ€™ Reply to Comment on â€œRisk-Adjusted Performance Measuresâ€• Pharmacoeconomics, 0, , .	3.3	1